Benitec Biopharma (BNTC) Profit After Tax (2019 - 2025)

Benitec Biopharma has reported Profit After Tax for 7 years, with the latest figure at -$133000.0 in Q4 2025.

• Quarterly Profit After Tax rose 93.94% year-over-year to -$133000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27.3 million (down 127.1% YoY) and the FY2025 annual result came in at -$37.9 million, down 73.93% from the prior year.
• Profit After Tax rose to -$133000.0 in Q4 2025 per BNTC's latest filing, from -$9.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $117000.0 in Q1 2024 and troughed at -$20.0 million in Q2 2023.
• A 5-year average of -$5.4 million and a median of -$5.0 million in 2021 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax plunged 13545.83% in 2022, then surged 102.69% in 2024.
• Over 5 years, Profit After Tax stood at -$4.8 million in 2021, then retreated by 12.24% to -$5.4 million in 2022, then fell by 25.63% to -$6.8 million in 2023, then jumped by 67.71% to -$2.2 million in 2024, then surged by 93.94% to -$133000.0 in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$133000.0, -$9.0 million, and -$8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.